WO2018194496A3 - Моноклональное антитело к pd-l1 - Google Patents

Моноклональное антитело к pd-l1 Download PDF

Info

Publication number
WO2018194496A3
WO2018194496A3 PCT/RU2018/050039 RU2018050039W WO2018194496A3 WO 2018194496 A3 WO2018194496 A3 WO 2018194496A3 RU 2018050039 W RU2018050039 W RU 2018050039W WO 2018194496 A3 WO2018194496 A3 WO 2018194496A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
antibodies
relates
biotechnology
dna
Prior art date
Application number
PCT/RU2018/050039
Other languages
English (en)
French (fr)
Other versions
WO2018194496A2 (ru
Inventor
Андрей Борисович УЛИТИН
Виктория Михайловна ЕКИМОВА
Екатерина Владимировна СОФРОНОВА
Юлия Сергеевна ЧЕРНЫХ
Сергей Андреевич АГЕЕВ
Анна Константиновна ВЛАДИМИРОВА
Алексей Александрович АЛЕКСАНДРОВ
Павел Алексеевич ГРЕБНЕВ
Валерий Владимирович СОЛОВЬЕВ
Яков Юрьевич УСТЮГОВ
Павел Андреевич ЯКОВЛЕВ
Тимофей Александрович НЕМАНКИН
Дмитрий Валентинович МОРОЗОВ
Original Assignee
Закрытое Акционерное Общество "Биокад"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020197033829A priority Critical patent/KR20190140979A/ko
Priority to NZ758093A priority patent/NZ758093A/en
Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"
Priority to EA201992206A priority patent/EA201992206A1/ru
Priority to AU2018255132A priority patent/AU2018255132A1/en
Priority to JP2020506702A priority patent/JP2020516323A/ja
Priority to MA47221A priority patent/MA47221A1/fr
Priority to US16/605,865 priority patent/US11236167B2/en
Priority to PE2019002020A priority patent/PE20191786A1/es
Priority to CN201880040390.1A priority patent/CN111247166B/zh
Priority to EP18786945.8A priority patent/EP3613770A4/en
Priority to BR112019021781A priority patent/BR112019021781A2/pt
Priority to CA3060395A priority patent/CA3060395A1/en
Publication of WO2018194496A2 publication Critical patent/WO2018194496A2/ru
Publication of WO2018194496A3 publication Critical patent/WO2018194496A3/ru
Priority to PH12019502298A priority patent/PH12019502298A1/en
Priority to CONC2019/0011458A priority patent/CO2019011458A2/es
Priority to ZA2019/07065A priority patent/ZA201907065B/en
Priority to JP2023031932A priority patent/JP2023081942A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Реферат Настоящее изобретение относится к области биотехнологии и предлагает антитела, которые специфично связываются с PD-L1. Изобретение также относится к ДНК, кодирующей указанные антитела, соответствующим экспрессионным векторам и способам продукции, а также к способам лечения с использованием указанных антител.
PCT/RU2018/050039 2017-04-17 2018-04-11 Моноклональное антитело к pd-l1 WO2018194496A2 (ru)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CN201880040390.1A CN111247166B (zh) 2017-04-17 2018-04-11 针对pd-l1的单克隆抗体
PE2019002020A PE20191786A1 (es) 2017-04-17 2018-04-11 Anticuerpo monoclonal para pd-l1
EA201992206A EA201992206A1 (ru) 2017-04-17 2018-04-11 Моноклональное антитело к pd-l1
AU2018255132A AU2018255132A1 (en) 2017-04-17 2018-04-11 Monoclonal antibody to PD-L1
JP2020506702A JP2020516323A (ja) 2017-04-17 2018-04-11 抗ｐｄ−ｌ１モノクローナル抗体
MA47221A MA47221A1 (fr) 2017-04-17 2018-04-11 Anticorps monoclonal à pd-l1
NZ758093A NZ758093A (en) 2017-04-17 2018-04-11 Monoclonal antibody to pd-l1
KR1020197033829A KR20190140979A (ko) 2017-04-17 2018-04-11 Pd-l1에 대한 단일클론 항체
US16/605,865 US11236167B2 (en) 2017-04-17 2018-04-11 Monoclonal antibody to PD-L1
BR112019021781A BR112019021781A2 (pt) 2017-04-17 2018-04-11 anticorpo monoclonal, célula hospedeira, método para produzir anticorpo, composição farmacêutica, combinação farmacêutica, método para inibir a atividade biológica e método de utilização do anticorpo
EP18786945.8A EP3613770A4 (en) 2017-04-17 2018-04-11 MONOCLONAL ANTIBODY AGAINST PD-L1
CA3060395A CA3060395A1 (en) 2017-04-17 2018-04-11 Monoclonal antibody to pd-l1
PH12019502298A PH12019502298A1 (en) 2017-04-17 2019-10-07 Monoclonal antibody to pd-l1
CONC2019/0011458A CO2019011458A2 (es) 2017-04-17 2019-10-16 Anticuerpo monoclonal para pd-l1
ZA2019/07065A ZA201907065B (en) 2017-04-17 2019-10-25 Monoclonal antibody to pd-l1
JP2023031932A JP2023081942A (ja) 2017-04-17 2023-03-02 抗ｐｄ－ｌ１モノクローナル抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017113141A RU2665790C1 (ru) 2017-04-17 2017-04-17 Моноклональное антитело к pd-l1
RU2017113141 2017-04-17

Publications (2)

Publication Number Publication Date
WO2018194496A2 WO2018194496A2 (ru) 2018-10-25
WO2018194496A3 true WO2018194496A3 (ru) 2019-01-10

Family

ID=63459922

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2018/050039 WO2018194496A2 (ru) 2017-04-17 2018-04-11 Моноклональное антитело к pd-l1

Country Status (21)

Country Link
US (1) US11236167B2 (ru)
EP (1) EP3613770A4 (ru)
JP (2) JP2020516323A (ru)
KR (1) KR20190140979A (ru)
CN (1) CN111247166B (ru)
AR (1) AR113223A1 (ru)
AU (1) AU2018255132A1 (ru)
BR (1) BR112019021781A2 (ru)
CA (1) CA3060395A1 (ru)
CL (1) CL2019002894A1 (ru)
CO (1) CO2019011458A2 (ru)
EA (1) EA201992206A1 (ru)
JO (1) JOP20190246A1 (ru)
MA (1) MA47221A1 (ru)
NZ (1) NZ758093A (ru)
PE (1) PE20191786A1 (ru)
PH (1) PH12019502298A1 (ru)
RU (1) RU2665790C1 (ru)
UY (1) UY37683A (ru)
WO (1) WO2018194496A2 (ru)
ZA (1) ZA201907065B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding antibodies against PDL1 and methods for their preparation
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
WO2022121846A1 (zh) * 2020-12-08 2022-06-16 博际生物医药科技(杭州)有限公司 Pd-l1抗体及其应用
WO2022271053A1 (en) * 2021-06-21 2022-12-29 Joint Stock Company "Biocad" Isolated bispecific antibody that specifically binds to cd47 and pd-l1
WO2023187460A1 (en) * 2022-04-01 2023-10-05 Mabtree Biologics Ag Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011128399A (ru) * 2008-12-09 2013-01-20 Дженентек, Инк. Антитела к pd-l1 и их применение для усиления функции т-клеток
US20140356353A1 (en) * 2009-11-24 2014-12-04 Medimmune Limited Targeted binding agents against b7-h1
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US5565323A (en) 1994-03-30 1996-10-15 Mitokor Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease
US5537905A (en) 1994-09-08 1996-07-23 Zimmer Industries, Inc. Nicked cutting rule
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
CA2612241C (en) * 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
US20110280877A1 (en) * 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
US9624298B2 (en) * 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
EP3553086A1 (en) * 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
KR101947702B1 (ko) * 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
AU2015301126B2 (en) 2014-08-05 2021-03-11 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
IL292449B2 (en) * 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding antibodies against PDL1 and methods for their preparation
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011128399A (ru) * 2008-12-09 2013-01-20 Дженентек, Инк. Антитела к pd-l1 и их применение для усиления функции т-клеток
US20140356353A1 (en) * 2009-11-24 2014-12-04 Medimmune Limited Targeted binding agents against b7-h1
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用

Also Published As

Publication number Publication date
US11236167B2 (en) 2022-02-01
JOP20190246A1 (ar) 2019-10-16
CA3060395A1 (en) 2019-11-18
AR113223A1 (es) 2020-02-19
PH12019502298A1 (en) 2020-07-06
CN111247166B (zh) 2024-03-26
EA201992206A1 (ru) 2020-02-21
UY37683A (es) 2018-11-30
CN111247166A (zh) 2020-06-05
ZA201907065B (en) 2020-09-30
MA47221A1 (fr) 2020-04-30
EP3613770A2 (en) 2020-02-26
NZ758093A (en) 2022-09-30
KR20190140979A (ko) 2019-12-20
PE20191786A1 (es) 2019-12-24
CO2019011458A2 (es) 2020-01-17
JP2023081942A (ja) 2023-06-13
BR112019021781A2 (pt) 2020-05-05
AU2018255132A2 (en) 2019-11-07
CL2019002894A1 (es) 2020-03-13
AU2018255132A1 (en) 2019-10-31
JP2020516323A (ja) 2020-06-11
US20200369771A1 (en) 2020-11-26
WO2018194496A2 (ru) 2018-10-25
RU2665790C1 (ru) 2018-09-04
EP3613770A4 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
PH12019502298A1 (en) Monoclonal antibody to pd-l1
PH12019502283A1 (en) Anti-lag3 antibodies
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
NZ738008A (en) Tigit-binding agents and uses thereof
PH12017500890A1 (en) Antibody drug conjugates
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
WO2016061608A8 (en) Monoclonal ανti-gpc-1 antibodies and uses thereof
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18786945

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020506702

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019021781

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018255132

Country of ref document: AU

Date of ref document: 20180411

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197033829

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018786945

Country of ref document: EP

Effective date: 20191118

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18786945

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112019021781

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191017